“Patients with malignant gastric outlet obstruction who have a good performance status are traditionally managed surgically to re-establish intake of solid food,” explained Dr Yorick van de Pavert (University Medical Centre Utrecht, the Netherlands) [1]. “Although this is an effective procedure, it has been associated with morbidities such as persistent gastroparesis.”
The ENDURO trial aimed to investigate whether an endoscopic approach could reduce the time to oral intake while maintaining comparable re-intervention rates. The research team randomised 98 patients with gastric outlet syndrome caused by a metastatic or unresectable malignancy (1:1) to undergo either endoscopic ultrasonography-guided gastroenterostomy or surgical gastrojejunostomy. The primary endpoints were time to oral intake of solid food and re-intervention rate at 6 months.
Patients in the endoscopy arm had a median time to initiation of oral intake of 1 day, compared to 3 days for patients in the surgery arm, representing a significant difference in favour of the endoscopy arm (HR 2.21; 95% CI 1.43-3.42; P=0.0003). Furthermore, the re-intervention rate for recurrent or persistent obstructive symptoms was 10% in the endoscopy arm and 12% in the surgery arm, clearly meeting the non-inferiority criterion. “In the endoscopy arm, 2 patients required surgical gastrojejunostomy and 3 patients received a second lumen-apposing metal stent,” Dr van de Pavert elaborated. “The 6 re-interventions in the surgery arm were all performed to install a feeding tube and/or provide parenteral nutrition.”
Finally, the median length of hospital stay was 1 day in the endoscopy arm and 4 days in the surgery arm (Relative Change 0.46; 95% CI 0.20-0.78).
In conclusion, endoscopic gastroenterostomy provided a faster time to resume oral intake and a shorter hospital stay while maintaining non-inferior re-intervention rates compared with a surgical approach.
- Van de Pavert YL, et al. Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO). OP001, Plenary Session, UEG Week, 4-7 October 2025, Berlin, Germany.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« EADV 2025 Highlights Podcast Next Article
High-dose obefazimod is efficacious in UC regardless of prior therapy exposure »
« EADV 2025 Highlights Podcast Next Article
High-dose obefazimod is efficacious in UC regardless of prior therapy exposure »
Table of Contents: UEGW 2025
Featured articles
Relapse rate and risk factors after anti-TNF withdrawal in UC
Reducing TME burden with a risk-stratified approach in early rectal cancer
Different outcomes of AI-read vs human-read endoscopies in the TITRATE study
Online First
Sugar-sweetened and non-sugar-sweetened beverages linked to MASLD risk
Rabeprazole may be the preferred high-dose PPI in severe eGERD
Promising signs from a novel Helicobacter Pylori vaccine
Relapse rate and risk factors after anti-TNF withdrawal in UC
TURN2: Well-prepared FMT shows efficacy in UC
Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis?
GLISTEN: Linerixibat meets primary endpoint in PBC-associated cholestatic pruritus
Reducing TME burden with a risk-stratified approach in early rectal cancer
PuraStat is effective and safe in real-world radiation proctopathy
Extended surveillance intervals after colorectal ESD may be safe and feasible
Different outcomes of AI-read vs human-read endoscopies in the TITRATE study
Can SIK3 inhibition become the Holy Grail for autoimmune diseases?
Mufemilast advances to phase 3 following positive phase 2 results in UC
High-dose obefazimod is efficacious in UC regardless of prior therapy exposure
Endoscopic approach preferred over surgery in gastric outlet syndrome
Related Articles
November 2, 2020
Post-colonoscopy colorectal cancers in IBD patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
